Manila Times Business
Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378
COPD study initiation expands WIN378 development into a second major respiratory diseaseWIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody for asthma and COPD, with Phase 3 initiation in asthma planned for Q4 2026 BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- Windward Bio, a private, clinical-stage biotechnology comp
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
Just now
Adaptive ML and AT&T Expand AI Collaboration to Scale Specialized Models Across Enterprise Workflows
Just now
LEIFRAS Co., Ltd. Announces Entry into Kawasaki City Through New School Club Support Contract
Just now
TOYO Co., Ltd. Secures Two Major Supply Agreements Totaling $185.6 Million in Cumulative Purchase Orders for the U.S. Market
Just now